TY - JOUR
T1 - A randomized, double-blind, placebo-controlled trial investigating cholesterol-lowering effects and safety of yellow yeast rice in adults with mild to moderate hypercholesterolemia A study protocol
AU - Jeong, Sewon
AU - Lee, Jaekyung
AU - Kwon, Oran
AU - Kim, Ji Won
AU - Oh, Bumjo
N1 - Publisher Copyright:
© 2018 the Author(s).
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Background: Elevated levels of blood lipids are well-documented risk factors for cardiovascular disease. For cardiovascular risk reduction, preventive strategies to lower blood cholesterol levels are essential, and these strategies include lifestyle modification and cholesterol-lowering agents. We aim to investigate the cholesterol-lowering effects and safety of yellow yeast rice in a randomized, controlled, double-blind, and parallel group study. Methods: Participants for this study will be selected based on the following inclusion criteria: 1. Voluntary agreement to participate and sign the written informed consent forms 2. Men and women (aged 20-45 years, premenopause) 3. Body mass index: 18 to 30kg/m2 4. Fasting low-density lipoprotein cholesterol (LDL-C) levels:≥ 130mg/dL 5. Fasting triglyceride levels: <300mg/dL Participants are randomly allocated to the placebo or yellow-yeast-rice-treated group. Participants with mild to moderately elevated LDL-C levels will consume 1 pouch of yellow yeast rice powder (containing monacolin K) or placebo twice daily for 8 weeks. Next, the lipid profiles will be evaluated. Results: The number of participants required for this study is 68, and is currently recruiting participants. Participants are randomly assigned to control group and intervention group. Conclusion: This is the first human intervention study to investigate the cholesterol-lowering effects and safety of yellow yeast rice in adults with mild to moderate hypercholesterolemia. Also, this is a randomized, double-blind, placebo-controlled trial that considers confounders, such as dietary habits, lifestyle factors, and genetic factors.
AB - Background: Elevated levels of blood lipids are well-documented risk factors for cardiovascular disease. For cardiovascular risk reduction, preventive strategies to lower blood cholesterol levels are essential, and these strategies include lifestyle modification and cholesterol-lowering agents. We aim to investigate the cholesterol-lowering effects and safety of yellow yeast rice in a randomized, controlled, double-blind, and parallel group study. Methods: Participants for this study will be selected based on the following inclusion criteria: 1. Voluntary agreement to participate and sign the written informed consent forms 2. Men and women (aged 20-45 years, premenopause) 3. Body mass index: 18 to 30kg/m2 4. Fasting low-density lipoprotein cholesterol (LDL-C) levels:≥ 130mg/dL 5. Fasting triglyceride levels: <300mg/dL Participants are randomly allocated to the placebo or yellow-yeast-rice-treated group. Participants with mild to moderately elevated LDL-C levels will consume 1 pouch of yellow yeast rice powder (containing monacolin K) or placebo twice daily for 8 weeks. Next, the lipid profiles will be evaluated. Results: The number of participants required for this study is 68, and is currently recruiting participants. Participants are randomly assigned to control group and intervention group. Conclusion: This is the first human intervention study to investigate the cholesterol-lowering effects and safety of yellow yeast rice in adults with mild to moderate hypercholesterolemia. Also, this is a randomized, double-blind, placebo-controlled trial that considers confounders, such as dietary habits, lifestyle factors, and genetic factors.
KW - Biomarkers
KW - Functional food
KW - High serum cholesterol
KW - Randomized controlled trial
KW - Treatment outcome
UR - http://www.scopus.com/inward/record.url?scp=85050891978&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000011634
DO - 10.1097/MD.0000000000011634
M3 - Article
C2 - 30045307
AN - SCOPUS:85050891978
SN - 0025-7974
VL - 97
JO - Medicine (United States)
JF - Medicine (United States)
IS - 30
M1 - e11634
ER -